CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope

Journal of Immunotherapy

Volumn 30, Issue 2, 2007, Pages 180-189

  Cui, Zhengrong ^a   Qiu, Fu ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

CTL; dsRNA; Tumor immunotherapy; Vaccine adjuvant

Indexed keywords

DOUBLE STRANDED RNA; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E7; PROTEIN E7 [44-62]; PROTEIN E7 [49-57]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOLOGIC MEMORY; MICE; PEPTIDES; POLY I-C; RNA, DOUBLE-STRANDED; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 34247630584     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211330.61019.6f     Document Type: Article

References (49)

1. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta. 2002;1589:1-13.
2. Seya T, Akazawa T, Uehori J, et al. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 2003;23:4369-4376.
3. Werling D, Jungi TW. TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol. 2003;91:1-12.
4. O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord. 2001;1:273-286.
5. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65-91.
6. Stark GR, Kerr IM, Williams BR, et al. How cells response to interferons. Annu Rev Biochem. 1998;67:227-264.
7. Yang YL, Reis LF, pavlovic J, et al. Difficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. Embo J. 1995;14:6095-6106.
8. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732-738.
9. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol. 2004;4:512-520.
10. Herman R, Baron S. Immunologic-mediated protection of Trypanosoma congolense-infected mice by polyribonucleotides. J Protozool. 1971;18:661-666.
11. Park JH, Baron S. Herpetic keratoconjunctivitis: therapy with synthetic double-stranded RNA. Science. 1968;162:811-813.
12. Partidos CD, Hoebeke J, Moreau E, et al. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization. Eur J Immunol. 2005;35:1521-1529.
13. Ichinohe T, Watanabe I, Ito S, et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol. 2005;79:2910-2919.
14. Fujimoto C, Nakagawa Y, Ohara K, et al. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol. 2004;16:55-63.
15. Meier WA, Husmann RJ, Schnitzlein WM, et al. Cytokines and synthetic double-stranded RNA augment the T helper 1 immune response of swine to porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol. 2004;102:299-314.
16. Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother. 2005; Epub.
17. Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res. 2006;23:1217-1226.
18. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163:57-61.
19. Schmidt KN, Leung B, Kwong M, et al. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol. 2004;172:138-143.
20. Sivori S, Falco M, Della Chiesa M, et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA. 2004;101:10116-10121.
21. Gelman AE, Zhang J, Choi Y, et al. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172:6065-6073.
22. Salem ML, Kadima AN, Cole DJ, et al. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005;28:220-228.
23. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005;433:887-892.
24. Fernando GJ, Khammanivong V, Leggatt GR, et al. The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. Eur J Immunol. 2002;32:1541-1549.
25. Fernando GJ, Stewart TJ, Tindle RW, et al. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J Immunol. 1998;161:2421-2427.
26. Lin CW, Lee JY, Tsao YP, et al. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer. 2002;102:629-637.
27. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55:3369-3373.
28. Fujita N, Kagamu H, Yoshizawa H, et al. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol. 2001;167:5678-5688.
29. He Y, Zhang J, Mi Z, et al. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol. 2005;174:3808-3817.
30. Kim TY, Myoung HJ, Kim JH, et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res. 2002;62:7234-7240.
31. de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol. 2002;168:1704-1709.
32. Kaech SM, Ahmed R. Immunology. CD8T cells remember with a little help. Science. 2003;300:263-265.
33. Shedlock DJ, Shen H. Requirement for CD4T cell help in generating functional CD8T cell memory. Science. 2003;300:337-339.
34. Sun JC, Bevan MJ. Defective CD8T cell memory following acute infection without CD4T cell help. Science. 2003;300:339-342.
35. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856.
36. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002;297:2060-2063.
37. Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88-93.
38. Borrow P, Tough DF, Eto D, et al. CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J Virol. 1998;72:7440-7449.
39. Buhlmann JE, Gonzalez M, Ginther B, et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol. 1999;162:4373-4376.
40. Behrens G, Li M, Smith CM, et al. Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol. 2004;82:84-90.
41. Tough DF, Zhang X, Sprent J. An IFN-gamma-dependent pathway controls stimulation of memory phenotype CD8+ T cell turnover in vivo by IL-12, IL-18, and IFN-gamma. J Immunol. 2001;166:6007-6011.
42. Tough DF, Sun S, Zhang X, et al. Stimulation of memory T cells by cytokines. Vaccine. 2000;18:1642-1648.
43. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-780.
44. Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naive and memory CD8T cells in vivo. Nat Immunol. 2000;1:426-432.
45. Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 1996;219:339-349.
46. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5:730-737.
47. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
48. Ashton-Rickardt PG. A license to remember. Nat Immunol. 2004;5:1097-1098.
49. Smith CM, Wilson NS, Waithman J, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol. 2004;5:1143-1148.